FTC, Amgen reach deal to allow $28 billion pharmaceutical merger
The Federal Trade Commission dropped its lawsuit to block Amgen’s merger with Horizon Therapeutics, reaching a deal it said would prevent anticompetitive behavior.
The Federal Trade Commission dropped its lawsuit to block Amgen’s merger with Horizon Therapeutics, reaching a deal it said would prevent anticompetitive behavior.